Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- IMM.LSE
- Price
- 2.44
- Stock movement down
- -0.13 (-5.06%)
- Company name
- ImmuPharma PLC
- Exchange
- (LSE ,
- Currency
- GBX )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.02B
- Ent value
- 1.02B
- Price/Sales
- -
- Price/Book
- 377.56
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -31.03%
- 1 year return
- 6.32%
- 3 year return
- -32.00%
- 5 year return
- -30.03%
- 10 year return
- -26.28%
Last updated: 2025-04-15
DIVIDENDS
IMM.LSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 377.56 |
| EV to Sales | -14528.21 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 416.44M |
| EPS (TTM) | -0.01 |
| FCF per share (TTM) | -0.00 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | -69.96K |
| Gross profit (TTM) | -88.80K |
| Operating income (TTM) | -2.53M |
| Net income (TTM) | -2.46M |
| EPS (TTM) | -0.01 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 126.93% |
| Operating margin (TTM) | 3614.67% |
| Profit margin (TTM) | 3519.56% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.08M |
| Net receivables | 348.72K |
| Total current assets | 2.19M |
| Goodwill | 0.00 |
| Intangible assets | 460.18K |
| Property, plant and equipment | 0.00 |
| Total assets | 4.06M |
| Accounts payable | 1.37M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 1.37M |
| Total liabilities | 1.37M |
| Shareholder's equity | 2.69M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -1.59M |
| Capital expenditures (TTM) | 2.00 |
| Free cash flow (TTM) | -876.73K |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -91.49% |
| Return on Assets | -60.61% |
| Return on Invested Capital | -91.49% |
| Cash Return on Invested Capital | -32.58% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.40 |
| Daily high | 2.67 |
| Daily low | 2.30 |
| Daily Volume | 687K |
| All-time high | 190.00 |
| 1y analyst estimate | 5.00 |
| Beta | 1.58 |
| EPS (TTM) | -0.01 |
| Dividend per share | - |
| Ex-div date | 14 Dec 2021 |
| Next earnings date | 3 Jun 2025 |
Downside potential
Loading...
Downside potential data
| IMM.LSE | S&P500 | |
| Current price drop from All-time high | -98.72% | -12.04% |
| Highest price drop | -99.55% | -56.47% |
| Date of highest drop | 4 Mar 2024 | 9 Mar 2009 |
| Avg drop from high | -64.35% | -11.07% |
| Avg time to new high | 90 days | 12 days |
| Max time to new high | 2016 days | 1805 days |
COMPANY DETAILS
Marketcap
1.02B
Marketcap category
Small-cap
Description
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the P140 (Lupuzor), a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140 which is in Phase II for chronic inflammatory demyelinating polyneuropathy, a progressive inflammatory condition of the nerves; and P140 in other indications for asthma, gout, periodontitis, and IBD. Its pre-clinical products include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations for serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection treatment. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Employees
5
Website
Investor relations
-
SEC filings
CEO
Country
UK
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found